A comprehensive review published in Current Molecular Pharmacology sheds light on the mechanisms and emerging treatments for hepatic ischemia-reperfusion injury (IRI), a leading complication in liver transplants and surgeries. The study, led by Kuldeep Singh and colleagues, underscores the role of oxidative stress, mitochondrial dysfunction, and inflammatory responses in IRI progression.
"Effective strategies must address multiple pathways, from antioxidant administration to surgical preconditioning," Singh explained. The review highlights promising therapies, including N-acetylcysteine, superoxide dismutase (SOD), and ornithine, which mitigate oxidative damage. Surgical approaches like ischemic preconditioning and machine perfusion also show potential in reducing injury.
The authors note the challenges in translating experimental findings to clinical practice. "While preclinical results are encouraging, large-scale human trials are needed," said co-author Jeetendra Kumar Gupta. The study also explores herbal compounds like curcumin and resveratrol, which exhibit anti-inflammatory and antioxidant properties.
With no current gold-standard treatment, the review calls for multidisciplinary efforts to improve patient outcomes. "Combining pharmacological and surgical interventions could revolutionize IRI management," Singh added.
Current Molecular Pharmacology
10.2174/1874467217666230803114856
Literature review
Hepatic Ischemia-reperfusion Injury: Protective Approaches and Treatment
The authors declare no competing interests.